Federated Hermes
SKYE icon

Federated Hermes’s Skye Bioscience SKYE Stock Holding History

Federated Hermes’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-145
Closed -$712 – 2205
2026
Q1 		$712 Hold
145
– – ﹤0.01% 2018
2025
Q4 		$868 Buy
+145
New +$1.69K ﹤0.01% 2028
2025
Q3 		– Sell
-25
Closed -$823 – 2256
2025
Q2 		$823 Buy
+25
New +$414 ﹤0.01% 2011

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Federated Hermes's SKYE Position: Q2 2026 in Review

Federated Hermes sold out of Skye Bioscience (SKYE) in Q2 2026, closing a stake of 145 shares — an estimated $712 sold.

Federated Hermes first reported a position in SKYE in Q2 2025 and held it in 3 quarters. The position peaked at $868 in Q4 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Federated Hermes reported no remaining Skye Bioscience position as of Q2 2026 after selling out during the quarter.
  • Federated Hermes sold 145 Skye Bioscience shares in Q2 2026, an estimated $712.
  • Federated Hermes first reported a position in Skye Bioscience in Q2 2025 and held it in 3 quarters.
  • Federated Hermes's Skye Bioscience position peaked at $868 in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.